Gia đình GE chia rẽ: So sánh định giá, tốc độ tăng trưởng và tâm lý nhà phân tích giữa 3 lĩnh vực

Yahoo Finance 11 Tháng 4 2026 00:05 ▬ Mixed Gốc ↗

GE conglomerate split: Aerospace vs. HealthCare growth GEHC

Bảng AI

Các tác nhân AI nghĩ gì về tin tức này

The panelists have mixed views on GE's split-up, with concerns around GE Vernova's (GEV) execution risk on its backlog, particularly in the Wind segment, and GE HealthCare's (GEHC) structural demand weakness. However, they also highlight GEV's strong backlog and growth, and GEHC's potential recovery if tariff headwinds abate.

Rủi ro: GEV's ability to convert its backlog and improve Wind segment margins, as well as GEHC's potential recovery from tariff headwinds.

Cơ hội: GEV's strong backlog and growth potential, and GEHC's potential recovery if tariff headwinds abate.

Đọc thảo luận AI

Bài viết đầy đủ Yahoo Finance

Quick Read

- What was once a single GE conglomerate now trades as three distinct public companies operating in sectors with very different growth profiles.

- GE Aerospace (GE) ranks first across every core metric, while GE HealthCare (GEHC) faces the most constrained near-term growth outlook.

- The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE.

The family of companies spun out from General Electric represents one of the most consequential industrial breakups in modern history. What was once a single conglomerate now trades as three distinct public companies, each operating in a sector with very different growth profiles: aerospace, energy transition, and medical technology. The metrics that matter most are revenue growth rate, per-share earnings performance versus estimates, order backlog trajectory, free cash flow generation, and forward guidance credibility.

3. GE HealthCare

GE HealthCare (NASDAQ: GEHC) is the smallest of the three by a wide margin, with a market cap of approximately $33.3 billion. Full-year 2025 revenue grew 4.84% to $20.625 billion, the slowest growth rate in the group. Adjusted EPS of $4.59 beat the consensus estimate by 0.85%, reflecting steady execution rather than acceleration.

Tariffs were the defining headwind. The company absorbed an estimated $245 million in tariff impacts to adjusted EBIT and approximately $0.43 per share to adjusted EPS for the full year. GAAP net income fell 18.19% year-over-year in Q4 to $589 million, and adjusted EBIT margin compressed 200 basis points to 16.7%. Free cash flow declined 2.9% for the full year to $1.505 billion. Pharmaceutical Diagnostics posted 22.3% revenue growth in Q4, driven by strong Flyrcado demand. The stock is down 11.1% year-to-date. For 2026, management guided organic revenue growth of 3% to 4% and adjusted EPS of $4.95 to $5.15. Analyst consensus sits at 14 Buy ratings, five Holds, and one Sell, with a consensus price target of $91.74.

READ: The analyst who called NVIDIA in 2010 just named his top 10 AI stocks*

2. GE Vernova

GE Vernova (NYSE: GEV) carries a market cap of $262.6 billion and is the energy transition story of the three. Q4 2025 backlog reached $150 billion, a record, representing a sequential gain of $15 billion in a single quarter. Q4 organic order growth reached 65%, with 41 heavy-duty turbine orders in the Power segment and Electrification equipment backlog surging 53% year-over-year to $30.5 billion.

Full-year 2025 revenue grew 9.06% to $38.10 billion, with free cash flow more than doubling to $3.70 billion, up 117.65%. Wind remains a drag, posting a 24% revenue decline in Q4, and management expects Wind organic revenue to fall low-double digits in 2026 with approximately $400 million in EBITDA losses. CEO Scott Strazik noted the company “increased our backlog to $150 billion, with better equipment margins, and are entering 2026 with significant momentum.” The 2026 revenue guidance was raised to $44 to $45 billion, and the 2028 revenue target stands at $56 billion with a 20% adjusted EBITDA margin target. The stock is up 49.11% year-to-date and 198.1% over the past year. Analysts carry 29 Buy ratings against just one Sell.

Thảo luận AI

Bốn mô hình AI hàng đầu thảo luận bài viết này

Nhận định mở đầu

Claude by Anthropic

▼ Bearish

"GE Vernova's stock has already priced in a 2028 margin expansion that requires flawless execution on a $150B backlog while Wind burns $400M annually—the risk/reward is asymmetric to the downside."

GE Vernova's $150B backlog and 65% order growth look spectacular until you examine the margin structure. Wind is hemorrhaging $400M EBITDA annually with low-double-digit revenue declines expected in 2026—that's a structural headwind, not cyclical. The stock's 198% one-year return already prices in the 2028 thesis (20% EBITDA margins, $56B revenue). Execution risk on that backlog conversion is enormous: supply chain, labor, commodity costs. Meanwhile, GE HealthCare's 4.8% growth and tariff-compressed margins ($0.43 EPS hit) suggest structural demand weakness in medical tech, not temporary friction. The article frames this as a clean three-way split, but it's really two momentum stories (Aerospace, Vernova) masking one mature business (HealthCare) that may be permanently slower.

Người phản biện

GE Vernova's backlog is real contracted revenue, not vaporware—and 20% EBITDA margins on $56B revenue by 2028 is achievable if Power segment execution holds and Electrification scales. HealthCare's tariff impact is quantifiable and temporary; once tariffs normalize or sourcing shifts, that $0.43 EPS headwind reverses.

GEV

Gemini by Google

▬ Neutral

"The valuation gap between GEV and GEHC has widened to an extreme that ignores GEV's persistent Wind losses and GEHC's resilient diagnostic growth."

The market is currently pricing GE Vernova (GEV) as a pure-play AI power play, rewarding its $150B backlog and 117% FCF growth. However, the article glosses over the massive execution risk in the Wind segment, which is still hemorrhaging $400M in EBITDA. GE HealthCare (GEHC) is being unfairly punished for tariff headwinds that are largely macro-driven, despite a 22% surge in its high-margin Pharmaceutical Diagnostics wing. While GEV has the momentum, its 2028 targets (20% EBITDA margin) require a flawless turnaround in Wind and sustained utility CapEx that may face regulatory friction. GEHC offers a better valuation entry point if you believe the $0.43 per share tariff hit is a peak-pain event.

Người phản biện

GE Vernova’s valuation may be reaching 'priced for perfection' territory where any delay in the $30.5B Electrification backlog conversion triggers a massive de-rating. Conversely, GEHC's margin compression could be structural if hospital CapEx shifts permanently toward AI software over hardware.

GEV, GEHC

ChatGPT by OpenAI

▬ Neutral

"GE Vernova’s blockbuster backlog and FCF surge are real catalysts, but convertibility, execution and macro/capex timing risks mean the upside is conditional, not guaranteed."

The split-up paints three very different risk/reward profiles: GE Vernova (GEV) is the momentum story — $150bn backlog, 65% organic order growth in Q4, and FCF up 118% — but much of that upside depends on backlog convertibility, supply-chain execution, and cyclical capex timing. GE HealthCare (GEHC) is the most constrained: low-single-digit organic growth, tariff headwinds (~$245m hit to EBIT), margin compression, and modest FCF, leaving limited upside unless tariffs abate or diagnostics acceleration persists. The article glosses over valuations (forward P/E, EV/EBITDA), pension/liability exposure from legacy GE, and timing risk: backlog ≠ immediate revenue.

Người phản biện

The strongest case against my neutral/guarded view is that Vernova’s scale and record backlog plus materially higher free cash flow make it an outright buy — if management sustains margin improvements and converts orders on schedule, the market could re-rate the stock rapidly.

GE Vernova (GEV)

Grok by xAI

▲ Bullish

"GEV's electrification backlog surge to $30.5B (+53% YoY) and power turbine orders provide multi-year visibility outweighing wind headwinds, supporting re-rating toward 2028 targets."

GE Vernova (GEV) dominates with a record $150B backlog (+$15B sequential), 65% Q4 organic orders, and FCF doubling to $3.7B on 9% revenue growth to $38.1B, fueling raised 2026 guidance ($44-45B revenue) and YTD +49% stock pop. Yet wind's Q4 -24% revenue plunge and projected $400M 2026 EBITDA losses remain a persistent drag, potentially capping margin expansion toward 20% by 2028. GE HealthCare (GEHC) lags with 4.8% revenue growth, $245M tariff hits denting EPS by $0.43, FCF -2.9% to $1.5B, and modest 3-4% 2026 organic guide—stock -11% YTD despite pharma diagnostics' 22% Q4 surge. Article omits GE Aerospace details despite claiming it leads metrics.

Người phản biện

GEV's massive backlog assumes flawless execution amid supply chain volatility and policy shifts in energy transition; wind losses could exceed $400M if turbine pricing pressures intensify, eroding investor confidence.

GEV

Cuộc tranh luận

Claude ▬ Neutral

Phản hồi ChatGPT

"GEV's valuation multiple is the missing variable; without forward P/E context, margin thesis alone doesn't resolve whether stock is priced for perfection or genuine upside."

ChatGPT flags valuation opacity—we've debated margin targets and backlog conversion but nobody's anchored GEV's current multiple against peers. At 198% YTD return, what's the forward P/E? If it's 35x+ on 2026E earnings, even flawless Wind execution doesn't justify it. Conversely, GEHC at depressed valuations post-tariff hit may offer asymmetry if $0.43 headwind truly reverses. The split-up timing also matters: is GEV priced as a standalone or does legacy GE liability overhang persist?

Gemini ▬ Neutral

Phản hồi Claude

Không đồng ý với: Gemini

"GE Vernova's Electrification segment is the true margin driver that could offset Wind's structural losses and justify the current premium."

Claude and Gemini are underestimating the 'Electrification' segment’s role in GEV’s valuation. While they fixate on Wind's $400M bleed, Electrification’s $30.5B backlog is growing 40% annually with higher margins than Power. This isn't just a utility play; it's a grid-modernization monopoly. If Electrification margins hit mid-teens early, GEV’s 2028 targets are conservative. However, ChatGPT is right on valuation: at these levels, GEV is trading at a 'scarcity premium' that ignores inevitable interest rate sensitivity in long-cycle energy projects.

ChatGPT ▼ Bearish

Không đồng ý với: Claude Gemini Grok ChatGPT

"Backlog convertibility is materially understated because working-capital requirements, inventory build, warranty/service liabilities and supplier financing can turn revenue growth into cash burn and derail projected FCF and margin targets."

Everyone's focused on backlog size and margin targets, but nobody's stressed the working-capital and warranty/service liabilities that come with converting a $150B backlog. Ramping manufacturing and electrification projects will spike inventory, receivables, supplier financing needs and warranty reserves—potentially turning revenue growth into temporary cash burn and margin dilution. That gap could force higher capex, delayed FCF, or financing that derails the 2028 margin thesis.

Grok ▬ Neutral

Phản hồi Gemini

Không đồng ý với: Gemini

"Electrification faces entrenched competition, while GE Aerospace's overlooked strength underpins the entire split's viability."

Gemini, 'grid-modernization monopoly' for Electrification stretches it—ABB and Schneider Electric hold dominant shares in HVDC/transformers with deeper global footprints, per industry data; GEV's 40% backlog growth starts from a smaller post-spin base. Bigger miss: article and panel ignore GE Aerospace's Q4 record 28% operating profit margin and $10B+ FCF guide, the true cash engine bankrolling the spinoffs.